Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection
暂无分享,去创建一个
T. Foster | E. Lavelle | W. V. van Wamel | T. Rogers | J. Geoghegan | Claire H A Hearnden | Claire H. A. Hearnden | H. Humphreys | J. Fennell | M. Tavakol | Aisling F. Brown | J. Leech | R. McLoughlin | D. Fitzgerald-Hughes | S. Lalor | Alison G. Murphy | K. Lacey | Dara P O'Halloran | Kate M. O’Keeffe | M. Mac Aogáin
[1] C. Weidenmaier,et al. The Fall of a Dogma? Unexpected High T-Cell Memory Response to Staphylococcus aureus in Humans. , 2015, The Journal of infectious diseases.
[2] T. Foster,et al. Manipulation of Autophagy in Phagocytes Facilitates Staphylococcus aureus Bloodstream Infection , 2015, Infection and Immunity.
[3] E. Wherry,et al. Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection , 2015, Science.
[4] S. Filler,et al. OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA , 111 ( 51 ) ISSN 0027-8424 , 2014 .
[5] Najaf A. Shah,et al. Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: An analysis of possible contributing host factors , 2014, Human vaccines & immunotherapeutics.
[6] P. Schlievert,et al. Models matter: the search for an effective Staphylococcus aureus vaccine , 2014, Nature Reviews Microbiology.
[7] V. Fowler,et al. Where does a Staphylococcus aureus vaccine stand? , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[8] T. Foster,et al. Targeted nasal vaccination provides antibody-independent protection against Staphylococcus aureus. , 2014, The Journal of infectious diseases.
[9] K. Mills,et al. Staphylococcus aureus Infection of Mice Expands a Population of Memory γδ T Cells That Are Protective against Subsequent Infection , 2014, The Journal of Immunology.
[10] T. Foster,et al. A short sequence within subdomain N1 of region A of the Staphylococcus aureus MSCRAMM clumping factor A is required for export and surface display. , 2014, Microbiology.
[11] A. Chong,et al. Protective Immunity against Recurrent Staphylococcus aureus Skin Infection Requires Antibody and Interleukin-17A , 2014, Infection and Immunity.
[12] Jesse B. Hall,et al. Immune Dysfunction Prior to Staphylococcus aureus Bacteremia Is a Determinant of Long-Term Mortality , 2014, PloS one.
[13] B. Segal,et al. In vitro polarization of T-helper cells. , 2014, Methods in molecular biology.
[14] G. Corey,et al. Methicillin-resistant Staphylococcus aureus: an evolving pathogen. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] E. Lavelle,et al. Nlrp-3-Driven Interleukin 17 Production by γδT Cells Controls Infection Outcomes during Staphylococcus aureus Surgical Site Infection , 2013, Infection and Immunity.
[16] H. Schønheyder,et al. A nationwide study of comorbidity and risk of reinfection after Staphylococcus aureus bacteraemia. , 2013, The Journal of infection.
[17] C. Welch,et al. Thirty-day mortality in UK patients with community-onset and hospital-acquired meticillin-susceptible Staphylococcus aureus bacteraemia. , 2013, The Journal of hospital infection.
[18] R. Betts,et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. , 2013, JAMA.
[19] K. Mills,et al. Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an Improved Acellular Pertussis Vaccine , 2013, PLoS pathogens.
[20] A. van Belkum,et al. Characterization of the Humoral Immune Response during Staphylococcus aureus Bacteremia and Global Gene Expression by Staphylococcus aureus in Human Blood , 2013, PloS one.
[21] C. Tapia P. [NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults]. , 2013, Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia.
[22] S. Cosgrove,et al. Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia. , 2012, The Journal of infectious diseases.
[23] Manmohan J. Singh,et al. The vaccine adjuvant alum inhibits IL‐12 by promoting PI3 kinase signaling while chitosan does not inhibit IL‐12 and enhances Th1 and Th17 responses , 2012, European journal of immunology.
[24] M. Aman,et al. Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. , 2012, The Journal of infectious diseases.
[25] D. Cooper,et al. Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors , 2012, Human vaccines & immunotherapeutics.
[26] H. Aamot,et al. Genotyping of 353 Staphylococcus aureus Bloodstream Isolates Collected between 2004 and 2009 at a Norwegian University Hospital and Potential Associations with Clinical Parameters , 2012, Journal of Clinical Microbiology.
[27] Y. Zhuang,et al. Role of gamma-delta T cells in host response against Staphylococcus aureus-induced pneumonia , 2012, BMC Immunology.
[28] S. V. van Hal,et al. Predictors of Mortality in Staphylococcus aureus Bacteremia , 2012, Clinical Microbiology Reviews.
[29] R. Proctor,et al. Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model , 2012, Human vaccines & immunotherapeutics.
[30] W. Brown,et al. CD4 T Cell Antigens from Staphylococcus aureus Newman Strain Identified following Immunization with Heat-Killed Bacteria , 2012, Clinical and Vaccine Immunology.
[31] B. Spellberg,et al. Development of a vaccine against Staphylococcus aureus , 2011, Seminars in Immunopathology.
[32] R. Gavrieli,et al. Lessons Learned from Phagocytic Function Studies in a Large Cohort of Patients with Recurrent Infections , 2011, Journal of Clinical Immunology.
[33] S. Engelmann,et al. Distinctive patterns in the human antibody response to Staphylococcus aureus bacteremia in carriers and non‐carriers , 2011, Proteomics.
[34] N. Rooijen,et al. SHIP‐deficient, alternatively activated macrophages protect mice during DSS‐induced colitis , 2011, Journal of leukocyte biology.
[35] Manuel T. Silva. Macrophage phagocytosis of neutrophils at inflammatory/infectious foci: a cooperative mechanism in the control of infection and infectious inflammation , 2011, Journal of leukocyte biology.
[36] V. Gant,et al. Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus? , 2011, Nature Reviews Microbiology.
[37] R. Landmann,et al. T and B Cells Are Not Required for Clearing Staphylococcus aureus in Systemic Infection Despite a Strong TLR2–MyD88-Dependent T Cell Activation , 2011, The Journal of Immunology.
[38] L. Bopp,et al. IFN-gamma enhances killing of methicillin-resistant Staphylococcus aureus by human monocytes more effectively than GM-CSF in the presence of daptomycin and other antibiotics. , 2010, Cytokine.
[39] Y. Iwakura,et al. Role of Interleukin-17A in Cell-Mediated Protection against Staphylococcus aureus Infection in Mice Immunized with the Fibrinogen-Binding Domain of Clumping Factor A , 2010, Infection and Immunity.
[40] J. Lindsay,et al. Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions , 2010, BMC Microbiology.
[41] E. Pietras,et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. , 2010, The Journal of clinical investigation.
[42] A. van Belkum,et al. Heterogeneity of the humoral immune response following Staphylococcus aureus bacteremia , 2010, European Journal of Clinical Microbiology & Infectious Diseases.
[43] T. Foster,et al. Molecular Characterization of the Interaction of Staphylococcal Microbial Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMM) ClfA and Fbl with Fibrinogen* , 2009, The Journal of Biological Chemistry.
[44] J. Farber,et al. Th1-Th17 Cells Mediate Protective Adaptive Immunity against Staphylococcus aureus and Candida albicans Infection in Mice , 2009, PLoS pathogens.
[45] H. Takada,et al. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome , 2009, The Journal of experimental medicine.
[46] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[47] Dirk Roos,et al. Chronic Granulomatous Disease: The European Experience , 2009, PloS one.
[48] C. Sasakawa,et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. , 2009, Immunity.
[49] K. Laupland,et al. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. , 2008, The Journal of infectious diseases.
[50] N. Litjens,et al. Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. , 2008, Journal of the American Society of Nephrology : JASN.
[51] P. Lipke,et al. The Antifungal Vaccine Derived from the Recombinant N Terminus of Als3p Protects Mice against the Bacterium Staphylococcus aureus , 2008, Infection and Immunity.
[52] D. Robinson,et al. Fnbpb Fibronectin-binding Proteins, Fnbpa and Phenotype Mediated by the Biofilm Staphylococcus Aureus a Novel , 2008 .
[53] Timothy Foster,et al. A Potential New Pathway for Staphylococcus aureus Dissemination: The Silent Survival of S. aureus Phagocytosed by Human Monocyte-Derived Macrophages , 2008, PloS one.
[54] D. Kasper,et al. IFN-gamma regulated chemokine production determines the outcome of Staphylococcus aureus infection. , 2008, Journal of immunology.
[55] F. Venet,et al. Monitoring Immune Dysfunctions in the Septic Patient: A New Skin for the Old Ceremony , 2008, Molecular medicine.
[56] Bodo Grimbacher,et al. STAT3 mutations in the hyper-IgE syndrome. , 2007, The New England journal of medicine.
[57] W. Greiner,et al. Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[58] K. P. Murphy,et al. Janeway's immunobiology , 2007 .
[59] C. Parish,et al. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester , 2007, Nature Protocols.
[60] O. Schneewind,et al. Vaccine assembly from surface proteins of Staphylococcus aureus , 2006, Proceedings of the National Academy of Sciences.
[61] A. Tzianabos,et al. CD4+ T cells and CXC chemokines modulate the pathogenesis of Staphylococcus aureus wound infections , 2006, Proceedings of the National Academy of Sciences.
[62] T. Foster. Immune evasion by staphylococci , 2005, Nature Reviews Microbiology.
[63] A. Watts,et al. Staphylococcus aureus Strains That Express Serotype 5 or Serotype 8 Capsular Polysaccharides Differ in Virulence , 2005, Infection and Immunity.
[64] B. Kocsis,et al. Comparison of Antibody Repertoires against Staphylococcus aureus in Healthy Individuals and in Acutely Infected Patients , 2005, Clinical Diagnostic Laboratory Immunology.
[65] M. Chatterji,et al. INFECTION-INDUCED MODULATION OF M1 AND M2 PHENOTYPES IN CIRCULATING MONOCYTES: ROLE IN IMMUNE MONITORING AND EARLY PROGNOSIS OF SEPSIS , 2004, Shock.
[66] S. Holland,et al. Long-Term Interferon-γ Therapy for Patients with Chronic Granulomatous Disease , 2004 .
[67] H. Wertheim,et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers , 2004, The Lancet.
[68] N. Van Rooijen,et al. Subpopulations of Mouse Blood Monocytes Differ in Maturation Stage and Inflammatory Response1 , 2004, The Journal of Immunology.
[69] K. Schroder,et al. Interferon- : an overview of signals, mechanisms and functions , 2004 .
[70] K. Schroder,et al. Interferon-gamma: an overview of signals, mechanisms and functions. , 2004, Journal of leukocyte biology.
[71] D. Christmann,et al. Role of Comorbidity in Mortality Related to Staphylococcus aureus Bacteremia: A Prospective Study Using the Charlson Weighted Index of Comorbidity , 2003, Infection Control & Hospital Epidemiology.
[72] P. van Endert,et al. A sensitive method for detecting proliferation of rare autoantigen-specific human T cells. , 2003, Journal of immunological methods.
[73] D. Christmann,et al. Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity. , 2003, Infection control and hospital epidemiology.
[74] H. Davies,et al. Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. , 2003, The Journal of infectious diseases.
[75] S. Foster,et al. σB Modulates Virulence Determinant Expression and Stress Resistance: Characterization of a Functional rsbU Strain Derived from Staphylococcus aureus 8325-4 , 2002, Journal of bacteriology.
[76] M. de Maeyer,et al. Staphylokinase-Specific Cell-Mediated Immunity in Humans1 , 2002, The Journal of Immunology.
[77] T. Foster,et al. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. , 2001, The Journal of infectious diseases.
[78] J. Shellito,et al. Requirement of Interleukin 17 Receptor Signaling for Lung Cxc Chemokine and Granulocyte Colony-Stimulating Factor Expression, Neutrophil Recruitment, and Host Defense , 2001, The Journal of experimental medicine.
[79] Julia Y. Wang,et al. Structural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[80] S. Plaisance,et al. Staphylokinase-Specific Cell-Mediated Immunity in Humans , 2001 .
[81] B. Spellberg,et al. Type 1/Type 2 immunity in infectious diseases. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[82] Richard B. Johnston,et al. Chronic Granulomatous Disease: Report on a National Registry of 368 Patients , 2000, Medicine.
[83] K. Heeg,et al. CpG‐oligodeoxynucleotides enhance T‐cell receptor‐triggered interferon‐γ production and up‐regulation of CD69 via induction of antigen‐presenting cell‐derived interferon type I and interleukin‐12 , 2000, Immunology.
[84] M. Helbert,et al. A simple flow cytometry assay using dihydrorhodamine for the measurement of the neutrophil respiratory burst in whole blood: comparison with the quantitative nitrobluetetrazolium test. , 1998, Journal of immunological methods.
[85] Zhao,et al. The dual role of interferon‐γ in experimental Staphylococcus aureus septicaemia versus arthritis , 1998, Immunology.
[86] A. Tarkowski,et al. Impact of interferon-gamma receptor deficiency on experimental Staphylococcus aureus septicemia and arthritis. , 1995, Journal of immunology.
[87] F. Chang,et al. Decreased cell-mediated immunity in patients with non-insulin-dependent diabetes mellitus. , 1995, Diabetes research and clinical practice.
[88] R. Coffman,et al. IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses. , 1988, Journal of immunology.